help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on January 16, 2003, doi:10.1164/rccm.200208-951OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200208-951OCv1
167/10/1341    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weiner, M.
Right arrow Articles by the Tuberculosis Trials Consortium
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiner, M.
Right arrow Articles by the Tuberculosis Trials Consortium,
American Journal of Respiratory and Critical Care Medicine Vol 167. pp. 1341-1347, (2003)
© 2003 American Thoracic Society

Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine

Marc Weiner, William Burman, Andrew Vernon, Debra Benator, Charles A. Peloquin, Awal Khan, Stephen Weis, Barbara King, Nina Shah, Thomas Hodge and the Tuberculosis Trials Consortium

University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX; Denver Public Health and Department of Medicine, University of Colorado Health Science Center and National Jewish Medical and Research Center, University of Colorado Schools of Pharmacy and Medicine, Denver, CO; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA; VAMC and George Washington University Medical Center, Washington, DC; and University of North Texas Health Sciences Center, Fort Worth, TX

Correspondence and requests for reprints should be addressed to Marc Weiner, M.D., Department of Medicine (111F), South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78284. E-mail: weiner{at}uthscsa.edu

To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus–seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial. In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration–time curve for 12 hours after the dose [AUC0–12] was 36 µg · hour/ml in failure/relapse versus 56 µg · hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin. Furthermore, two patients who relapsed with Mycobacterium tuberculosis monoresistant to rifamycin had very low concentrations of isoniazid. Finally, isoniazid acetylator status determined by N-acetyltransferase type 2 genotype was associated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/rifampin. No rifamycin pharmacokinetic parameter was consistently and significantly associated with outcome (p > 0.10). Because low isoniazid concentrations were associated with failure/relapse, a drug with consistently greater area under the concentration–time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.

Key Words: tuberculosis • isoniazid • rifapentine • treatment • pharmacokinetics




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Goutelle, L. Bourguignon, P. H. Maire, M. Van Guilder, J. E. Conte Jr., and R. W. Jelliffe
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2974 - 2981.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. Nuermberger and D. A. Mitchison
Once-Weekly Treatment of Tuberculosis with the Diarylquinoline R207910: A Real Possibility
Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 2 - 3.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Veziris, M. Ibrahim, N. Lounis, A. Chauffour, C. Truffot-Pernot, K. Andries, and V. Jarlier
A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis
Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 75 - 79.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Gumbo, A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano
Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2329 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
I. M. Rosenthal, K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger
Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. S. Wallis
Can Studies of the Early Bactericidal Activity of Rifapentine Tell Us How to Prevent Acquired Rifamycin-Resistant Relapse?
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 4 - 5.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. A. Sirgel, P. B. Fourie, P. R. Donald, N. Padayatchi, R. Rustomjee, J. Levin, G. Roscigno, J. Norman, H. McIlleron, D. A. Mitchison, et al.
The Early Bactericidal Activities of Rifampin and Rifapentine in Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 128 - 135.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Kinzig-Schippers, D. Tomalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, M. Rodamer, I. Cascorbi, O. Doroshyenko, F. Sorgel, and U. Fuhr
Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Peloquin
Use of Therapeutic Drug Monitoring in Tuberculosis Patients
Chest, December 1, 2004; 126(6): 1722 - 1724.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. M. Gordin
Rifapentine for the Treatment of Tuberculosis: Is It All It Can Be?
Am. J. Respir. Crit. Care Med., June 1, 2004; 169(11): 1176 - 1177.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Weiner, N. Bock, C. A. Peloquin, W. J. Burman, A. Khan, A. Vernon, Z. Zhao, S. Weis, T. R. Sterling, K. Hayden, et al.
Pharmacokinetics of Rifapentine at 600, 900, and 1,200 mg during Once-Weekly Tuberculosis Therapy
Am. J. Respir. Crit. Care Med., June 1, 2004; 169(11): 1191 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 288 - 300.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. A. Mitchison
Role of Isoniazid in Once-Weekly Rifapentine Treatment of Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1298 - 1299.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society 		  SOTA, FL